Roquefort Therapeutics PLC (LSE:ROQ) CEO Ajan Reginald talked with Proactive's Stephen Gunnion about the binding share purchase agreement with Pleiades Pharma for its wholly-owned subsidiary, Lyramid. The $10.8 million deal includes both shares and cash. Reginald highlighted that Roquefort initially acquired Lyramid for £1 million in 2021 and invested another £1 million to develop its assets. The sale validates Roquefort’s strategy of acquiring and developing high-potential biotech assets. He emphasised that the Midkine portfolio—including Midkine mRNA, Midkine SSO, and legacy antibody assets—will now be advanced by Pleiades. Through this transaction, Roquefort secures a material stake in Pleiades, which already holds valuable clinical assets. Reginald noted that Pleiades' track record of selling to major pharmaceutical companies provides potential upside for Roquefort shareholders. Looking ahead, Roquefort will focus on its MK cell therapy and STAT-6 programs. Reginald confirmed the company plans to complete further licensing deals and trade sales this year. For more insights into Roquefort Therapeutics’ strategic plans, watch the full interview. Don’t forget to like this video, subscribe to Proactive’s YouTube channel, and enable notifications for future updates. #RoquefortTherapeutics #Biotech #PharmaDeals #Investment #AjanReginald #PleiadesPharma #Midkine #BiotechInvesting #PharmaNews #StockMarket #HealthcareInnovation